Praxis Precision Medicines Insider Receives 10,520 Stock Options

Rhea-AI Filing Summary

Praxis Precision Medicines, Inc. (PRAX) reported a routine insider equity award through a Form 4 filed on 27 June 2025. Director Jeffrey Chodakewitz received a grant of 10,520 stock options on 26 June 2025 at an exercise price of $44.04 per share. The options vest in 12 equal monthly installments over one year beginning the grant date and carry an expiration date of 26 June 2035. No open-market purchases or sales of common stock were disclosed, and Mr. Chodakewitz’s direct derivative holdings after the transaction total 10,520 options. The filing reflects a standard compensation-related award rather than a change in the director’s economic exposure to outstanding common shares.

Insights

Financial Analyst

TL;DR: Routine option grant to director; no immediate share movement; neutral impact.

The Form 4 discloses a typical annual equity incentive: 10,520 options granted to Director Jeffrey Chodakewitz at $44.04, vesting monthly over 12 months and expiring in 2035. Because the transaction is an award (code “A”) and involves derivatives rather than common stock, it does not alter the public float or signal insider sentiment through buying/selling. Such grants are common for biotech boards and are unlikely to sway valuation or liquidity. Investors should view the filing as administrative rather than a catalyst.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chodakewitz Jeffrey

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$44.04	06/26/2025		A		10,520		(1)	06/26/2035	Common Stock	10,520	$0	10,520	D

Explanation of Responses:

1. The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 26, 2025.

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Praxis Precision Medicines (PRAX) stock options were granted in this Form 4?

The director received 10,520 stock options.

What is the exercise price of the PRAX options granted to Jeffrey Chodakewitz?

The exercise price is $44.04 per share.

When do the PRAX options begin vesting and over what period?

They vest in 12 equal monthly installments starting on 26 June 2025.

What is the expiration date of the granted PRAX stock options?

The options expire on 26 June 2035.

Did the Form 4 report any open-market purchases or sales of PRAX common stock?

No, the filing only reported an option grant; no shares were bought or sold.